Andrew Perlman

ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.

Innate Immune, Inc. discovers and develops therapeutics for asthma and autoimmune diseases. The company provides services to the hospitals and health care centers. Innate Immune was founded by Andrew J. Perlman and is headquartered in Stanford, CA

Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA.

Spitfire Pharma, Inc. provides drug development and research services. The firm’s products include SP-1373, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company was founded by John J. Nestor, Jr. and is headquartered in South San Francisco, CA.

Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California.